ABSTRACT

Alfuzosin, a quinazoline derivative, acts as a selective antagonist of α1-adrenoceptor-mediated contraction of bladder neck, proximal urethral, and prostatic smooth muscle. Bladder outlet resistance resulting from benign prostatic hyperplasia (BPH) is consequently reduced. Alfuzosin is approved in Europe for the treatment of symptomatic BPH.